Full Transcript Introduction and Guest Credentials 0:00 It is my absolute pleasure to introduce our next guest, a physician 0:03 who truly sits at the leading edge of longevity and regenerative medicine. 0:07 Doctor Elizabeth Yurth is the co-founder and chief medical officer of the Boulder 0:11 Longevity Institute, 0:12 which she established back in 2006 with a simple but powerful mission 0:17 to bring in her words, tomorrow's medicine today to the people she serves. 0:21 Doctor Yurth 0:22 earned her medical degree from the University 0:24 of Southern California's Keck School of Medicine, 0:26 completed her residency at UC Irvine, and holds a prestigious Sports 0:30 and Spine Fellowship through the Stanford affiliated Store program. 0:33 She's double 0:34 certified in physical medicine and rehab and in anti-aging and medicine, 0:39 and she carries an extraordinary list of advanced fellowships in cellular, 0:43 regenerative and epigenetic medicine, along with national peptide certification 0:47 through a forum with more than 30 years in clinical practice and over 600 hours 0:52 of dedicated training in longevity, cellular medicine, and peptide 0:55 therapeutics, she's become one of the most sought after educators in this space. 1:00 She lectures nationally for the A forum, and the International Peptide Society, 1:05 serves on the Scientific Advisory Board for Longevity Labs, and teaches 1:08 thousands of practitioners and patients through her Human Optimization Academy. 1:13 In today's conversation, we have something especially timely. 1:17 Doctor youth will be giving us a firsthand 1:18 update on the FDA proceedings on peptides, which she personally testified in 1:23 at the end of July. 1:24 So we truly are getting news from the front lines, 1:27 and then we go on to have an amazing conversation 1:30 about how to use different peptides in different contexts. 1:33 Now, simply put, when it comes to peptides and the science 1:37 of getting ourselves to age better, there are few people on the planet 1:40 more knowledgeable or more generous with that knowledge. 1:43 Please join me in welcoming the brilliant Doctor Elizabeth Yurth 1:47 I you know, I always love spending time with you 1:50 and talking those years we just spent the last hour talking. 1:54 So now we're going to actually record. 1:55 But it's so nice to be here and be able to talk more peptides. 1:58 Yeah. 1:59 So more people are really like literally our favorite topic. 2:02 So number one, I'm going to explain my face quickly. 2:05 I'm not wearing any makeup, guys. 2:06 I look a little weird because I had micro needling on this 2:09 and I can't put any makeup on. 2:11 So for those of you watching, that's why not. 2:13 Looks a little odd. 2:14 Now enough about that. 2:16 Let's move on to. 2:18 First of all, I just want to clarify for the audience 2:21 where we are in the regulatory landscape right now. 2:24 You spent all of last week in Washington 2:28 with a host of other providers 2:32 and compounding pharmacy owners and politicians and all kinds of people 2:36 going through this FDA process around it was seven peptides. 2:40 We now six have survived the day. Right. 2:43 Can you talk to us very quickly about what you saw happening, where we're at? 2:48 What does this mean? 2:50 Because you and I 2:51 are both seeing things on Instagram that's making us kind of just right 2:55 smack our heads. 2:55 So could we just bring some clarity to the picture here? 2:58 So first of all, you know,
FDA Peptide Regulatory Update 3:00 I've kind of recently only gotten into this a little bit of political world, 3:03 and it's never been something I've really wanted to stumble into. 3:07 And yet I found myself a little bit now, you know, feeling compelled that, 3:13 you know, with physicians, we aren't we we we don't like this world. 3:17 You know, I know you have a son who's going into law. 3:19 Last thing doctors want anything to do with in general as law, right? 3:22 And yet you mean it's a necessary evil, right? 3:25 Right. 3:26 And we as physicians start being a little bit more advocates 3:29 out there than other people are going to be. 3:32 And that's where I think we need more, more, 3:34 more physicians to actually get involved in this. 3:36 And and before I went out to, to D.C., I was actually in Montana, 3:41 and I was I was talking to you about this in Montana recently. 3:44 Last year passed a right to try law here in Colorado. 3:48 We have a right to try 3:48 if you have a terminal disease in Montana, they passed a right to try law. 3:52 If you and your physician agree that you want to do something, you can do it there. 3:57 So biotech companies are moving there to try things. 3:59 That's kind of where I would like to see our world go. 4:01 Should really be the patient and physicians decision on what they want 4:06 to do. 4:06 And obviously, 4:06 if you're a horrible physician and you want to do things 4:09 that kill people, you're probably going to be a practice law. 4:11 So most of us are going to stay within the lines of safety. 4:13 But I think that's really important that we really need to look at this 4:16 peptide step that we're taking is hopefully the first step in making 4:21 the care back to the patient, the patient being their own advocate. 4:26 The patient working with the physicians is to have 4:29 some other governmental agency or pharmaceutical company being in charge. 4:33 And that's where I really hope that we start focusing our attention 4:36 a little bit more. 4:37 So and as you and I talked about, you know, 4:39 I think there's a lot of misconceptions about what happened last week 4:43 because everybody said all of these are off the category to us. 4:45 They came off the category two less back in April. Right. 4:48 But that did not authorize compounding. 4:50 They basically stayed in this limbo zone. 4:53 So they were no longer on the main not to do lists. 4:56 They were not on the made list. 4:58 They just were in limbo. 4:59 And that's kind of still where they are, I'm afraid. 5:02 What happened last week was that we all testified, and this was a 5:07 two days of really long, long days. 5:10 I mean, the first day 5:11 went from eight in the morning till eight at night with people arguing, 5:14 arguing for and against the safety of peptides. 5:18 And really, it wasn't even efficacy at this point. 5:21 It really is more are they are these categorized appropriately 5:26 and are they safe? 5:27 And we presented a whole lot of data. 5:30 So it was a close vote. 5:32 But six out of the seven peptides did make it through from the Physician 5:37 advisory Committee, recommending to the FDA 5:40 that these be moved into category one, 5:46 meaning that the compounding pharmacies have full right to compound them. 5:50 What we need to remember is that nothing right now is legal. 5:54 All right. 5:55 There's three separate events and the market keeps kind of 5:58 collapsing those all into one. 6:00 So removal from category two happened a pcap recommendation happened, 6:05 but the actual placement into category one 6:09 compatible list is maybe a year out. 6:14 We have no idea. 6:16 You know, what happens now is the FDA publishes 6:18 a notice, a proposed rulemaking, I think it's called. 6:22 And then there's 6:22 this public comment period where people can put back in comments again. 6:26 And then there's the final rule in the Federal Register. 6:30 And that's once that final rule is that's when those can be 6:34 legitimately pushed onto category one and the compounding pharmacies make. 6:38 So right now we're back into the same green zone that we were before. 6:41 And and you know and so is it a first step. Yes. 6:45 We at least have moved them into the point where the compounding Advisory 6:49 Committee has said, yes, the FDA still has the ultimate decision. 6:53 Now, most of the time, the FDA will go with what 6:57 Peacock recommends, but there have been cases where they have not. 7:01 Well, in Peacock has never been composed of the constituents it's composed of. 7:06 Now, that's the other thing. 7:07 I think that what's changed here, and this is the work of RFK 7:11 at the end of the day, is that he created a PKC committee 7:15 that are not just another bunch of FDA scientists, so that you're 7:19 not in an echo chamber with two groups of the same group of people 7:22 supporting each other's opinions. 7:24 So he went out and, you know, his credit really found like, 7:29 whether it's physicians, compounding pharmacy owners, 7:33 like people who've actually worked with peptides 7:36 to try and amass a body of knowledge upon which to try 7:41 and start to bring context to these conversations and decisions, 7:45 which is the only reason, frankly, why we've even moved half a step closer to 7:51 six of the 7:52 eight members that were sort of the positive members of TC 7:56 were from clinics practices where peptides are administered. 8:00 Right. 8:01 And so there certainly was a positive bend that way. 8:03 And I will tell you, the FDA didn't like that. 8:05 No, it actually brought that into point 8:07 quite a bit that these people had ulterior motives. 8:09 I think the physicians that I very well know, 8:12 the physicians who were on the panel, all of them are very 8:16 you know, they are physicians who are not doing things for money. 8:18 They're doing things for the best interests of their patients. 8:20 And and that's really what was presented this we presented so much data 8:24 to the FDA on safety of these people say there's no human data. 8:28 There is. We've been collecting human data. 8:30 We had 16 million cases of BPC being administered 8:34 with a .00 3% complication rate. 8:37 The data is out there. 8:39 They just don't want to look at that data. 8:41 The only want to look at these double blind, 8:43 placebo controlled states, which we don't have yet, 8:45 but we have so much data from clinics now that we've been collecting 8:51 and looking at safeties and calling poison control centers and calling 8:55 areas to find out. Do you ever see these things? 8:57 Right. 8:58 And interesting that the FDA brought up the few, you know, 9:01 a few cases that really had nothing to do with, you know, what we do? 9:04 You know, these like the Rad Fest cases where two people got 9:07 it wasn't even peptides in that case, like peptides in case or this NAD case, 9:12 the young woman just just died, you know, again, not a peptide. 9:16 And yet they brought up these cases, as you know, reasons 9:19 we should not be authorizing these these are unsafe things. 9:22 So we'll see what happens. 9:24 And you know, it's very frustrating because if you go look at most drugs 9:28 and the adverse events that have been reported 9:30 on most approved medications, I mean, you'll find deaths 9:34 from aspirin and Tylenol and way more mind the prescription way more. 9:39 There is not a prescription drug out there. 9:41 And I will say, I've been using peptides in my past by longer 9:43 than just about anybody over ten years or a decade of using these. 9:46 And I use a lot of, you know, traditional medications as well. 9:49 And I will honestly say, and I know this, people will argue 9:52 this, I have never seen a significant complication from the peptides 9:55 I use used appropriately in the right patient. I've never seen. 9:58 I can say that about nothing else, that I prescribe 10:02 nothing else, and certainly not for a lot of things I use 10:05 for like arthritis, where we have NSAIDs, which are responsible 10:09 for a rendus number of deaths, right, or steroids or surgeries. 10:14 So I think that even if you look at the FDA themselves 10:18 authorizing the peptide GLP ones of all the peptides we have, 10:23 ones are probably one of the ones that has more side effects, right? 10:25 Yes. Authorized that one. Exactly. 10:28 Exactly like you don't. 10:30 You can't get gastroparesis from BPC 157, right? 10:34 You just can't. 10:36 I mean, in a disaster, maybe we see people that develop anhedonia or, 10:42 you know, like, and these are people that already have imbalances going on 10:46 and somehow it triggers them the wrong way. 10:49 But I mean, it's anyway, it's remarkable how to sort of stay 10:55 now in that we this battle isn't over, that we need to keep you know about it 11:00 more writing letters, keeping it, keeping that we need physicians involvement. 11:03 We need to, you know, rightfully, we need to keep collecting data. 11:07 Yeah. It is hard. 11:08 You know, as a physician, 11:10 you know, the last thing I want to do is be collecting all this data 11:13 and send it off to somebody. 11:14 You almost need a full time person to be able to that. 11:16 We're trying to make that simpler for positions 11:17 so we can get data more simply and really get the, you know, 11:21 the more and more and more data. 11:22 But I think we hear so often there's not data support these. 11:25 And there is it's just not the 11:28 controlled study data. 11:29 Yeah. 11:30 Which, you know, I mean we're not going to I don't want to 11:33 I don't want to stay on this too long. 11:34 But even the double blind, controlled, placebo controlled study 11:38 has its own limitations. 11:40 Well, they're artificial conditions that are created, and you still can't 11:45 you still can't account for all the external variables. 11:48 So often some of those drugs actually down the road right 11:52 now, we've been using, you know, these peptides for over a decade. 11:55 So, you know, down the road, a drug that passed its little 12:00 trials ended up being a problem and being pulled off market. 12:03 Right. 12:04 So, you know, we have now all this data. 12:07 Yeah. All right. 12:08 So that's the state and nation guys I you know we're recording this podcast days 12:12 before the summit starts. 12:13 Almost like this was a last minute episode. 12:16 I really wanted to include this piece of information in this summit 12:20 because Lord knows if the summit needs anything. 12:22 It's context and understanding 12:24 about what's happening in the industry right now, which is really important. 12:28 But now let's move on to the next piece of the puzzle, which we thought we would. 12:33 You know, we everybody's talking about jail peas. 12:35 Everybody's talking about all the things. 12:36 One thing I would love to talk about is what have you observed clinically. 12:42 And this is going to sound boring to 12:43 people, but honestly, with BPC 157 and even when it's 12:48 when it's stacked with the TB 500, when we're looking 12:51 at healing of musculoskeletal injuries, whether it's tendons, 12:54 ligaments, muscles, bones, whatever it is, where are you seeing them really work? 12:59 And, you know, 13:00 we're going to bring in a third peptide here, 13:02 not even a peptide, but just the third component 13:04 that people just don't think about when they're thinking 13:07 about healing musculoskeletal injuries. 13:09 So I'm going to let you fly with this. 13:11 But basically that's what we decided we would pick as our topic 13:15 because we there's about 500 of them we could have chosen. 13:18 So let's just go with that one. 13:20 Yeah I think this is really important because honestly, you know, 13:24 some of you guys know I come from an orthopedic world 13:27 and I really think that orthopedics 13:32 in itself is really not 13:35 it's kind of lost baby because people's pain, people's arthritis. 13:40 People think, oh, well, that's that. 13:42 But they don't think of it as something that's going to kill people 13:45 like heart disease 13:46 or, you know, some of these other, you know, other dysfunctions. 13:49 And so we sort of put it down a layer when we're looking at some of the peptides 13:53 and their effectiveness for things like like a metabolic disorders. 13:57 Right. 13:57 Like the, you know, for some we look at metabolic 14:01 disorders says, okay, well we know diabetes kills millions of people. 14:04 We know kills millions of people. 14:05 And we don't look at arthritis the same way. 14:08 And so one of my passion projects, and, you know, it's one of the reasons 14:13 I actually flew to, to Montana last week, was before 14:16 last was to meet with the biotech company 14:18 that's working on cartilage regeneration with exactly the same thing. 14:20 They said. 14:20 Nobody's putting their money here because it honestly is not something 14:25 that everybody has as much interest in as cancers and heart diseases. 14:28 But I think it really is probably the most 14:32 debilitating of almost everything we deal with. 14:36 And so when we look at things like BPC and TD 500, I think they are 14:41 marvelous entity for helping tendonitis, you know, inflammatory stuff in a joint. 14:45 You hurt yourself, you sprain your ankle. 14:47 They do remarkably well. 14:49 Remember increasing vascular flow or getting stem cell migration there. 14:53 Those are all the things you need to heal 14:55 an acute injury or for instance, post-surgical. 14:59 Love them.
Peptides for Musculoskeletal Healing 15:00 Amazing outcomes by you. 15:03 I have somebody who just had an ACL reconstruction 15:06 because those are the pieces we need, right? 15:08 We need increased vascular flow. 15:09 We need stem cell migration. 15:10 We need normal actin polymerization. 15:13 So we need all these things that these peptides do 15:16 where they fall short unfortunately I think is in that arthritis. 15:21 Well because they're great for anti-inflammatory. 15:25 They are great for helping tendons, ligaments. 15:28 They're not so great at regenerating cartilage. 15:31 So what do you do with a patient that has significant cartilage loss. 15:37 And they come to me and they think okay I want BPC TB 500. 15:42 Is that going to get them where they want to go? 15:45 Probably not. Right. Probably. 15:47 If I have somebody who has, you know, significant cartilage loss in a joint, 15:51 maybe I can get some of the inflammation down. 15:53 But I'd probably not going to dramatically restore their function. 15:56 And so that's where these peptides fall a little bit short. 15:58 We have to say okay, where can we pull in other things. 16:01 And then use the peptides adjunctive 16:04 but not as the sole treatment. 16:06 Because I think anybody who tells you they are going to cure your artwork knee 16:11 is probably giving you a load of BS. 16:14 They're not. 16:15 Well, yeah. 16:16 What about the something like a CFPB, which is much more focused 16:20 on being an anti-inflammatory peptide? 16:23 Can that be a player here again? 16:25 I mean we're not talking about necessarily 16:27 cartilage regeneration, although we could talk quickly about Edwin 16:30 Lee, Doctor Edwin Lee's study that he, you know, he injected 16:33 BPC intra articulately into knees with Halo Nordic said. 16:38 I think it was anything else. 16:40 And he showed so. 16:42 So I think he has he had you know, last I saw maybe 20 patients, 16:46 maybe it was 30 now. 16:47 But again, pain relief is different. 16:51 Yeah. 16:51 It's different than all sunlight restored function. 16:54 So and again I will tell you like you I have horrible I have end stage my knees. 16:59 But I don't have pain because I do have the inflammation under control. 17:04 Are my knees normal? 17:06 No, I still have some Lockey to my knees. 17:09 There's still, you know, grinding to my knees. 17:11 There's positions I can't get into. 17:12 There's things like, you know, trying to do a deep squat I can't do. 17:16 It's just as mechanically the joint does not have the stability to do those things. 17:21 So functionally I'm pretty good at my where I would love to be. 17:25 No, I'm not where I was when I was 20 and you know, and had perfect knees. 17:29 So but I gotten the inflammation control. 17:31 And yes, CFPB can certainly be an adjunct there as can copper. 17:35 Right. 17:35 So copper also in restoring some of the collagen function 17:39 that so the memory you're dealing with most of these things again in soft tissue 17:43 cartilage is this very own entity. 17:44 And if you have an acute care of a car 17:46 like that, maybe increasing vascular flow depending on where the tear is, 17:49 can help that to heal a little bit in a younger person. 17:52 But where I think we need to sort of be a little skeptical 17:56 is that we're going to use peptides 17:57 in this realm of where's that that play a role on helping cartilage? 18:01 I think we have to use them as adjunctive tools to other things. 18:05 You and I have talked about Pedersen poly sulfate as one of those tools 18:08 has probably sulfate, which is a approved drug called on, 18:11 and it actually works on reducing all of the 18:15 inflammatory markers that are causing destruction of the cartilage. 18:19 But also these substances 18:22 can also help to potentially rebuild cartilage. 18:26 So at least in the studies a year post on Pedersen, 18:29 we saw significant improvements in cordless space. 18:32 You can't say that from any peptide. 18:34 That, including Edwin Lee's studies, did not show 18:38 significant on MRI scan imaging changes in caudal structure. 18:41 Okay, okay. 18:43 But let's let's say they if I use Pedersen to help that, 18:47 I'm also going to pull in my other things to BPC times in beta 500. 18:51 So I think that those are going to still be really adjunctive there. 18:55 I do think where we may be looking at some hope 18:58 is maybe looking at some of the mitochondrial peptides, 19:02 because what we've now found is that one of the biggest dysfunctions, 19:06 just like what we're finding with every tissue, 19:10 one of the biggest dysfunctions lies in 19:13 when we have cartilage loss is in the mitochondria of the cartilage. 19:16 Wow. Yeah. 19:17 So what if we rebuild mitochondria? 19:21 Can we actually within the countryside, remember, these are cells 19:24 just like any other cell. 19:25 Rebuild the mitochondria within the site. 19:29 Can we see regeneration? 19:31 And there's some suggestion that that might be the case that using 19:35 mitochondrial peptides like SS 31, like mod SC may be helpful? 19:41 Dad is not out there yet. We don't have the data. 19:43 So look at some of the MRI scan. 19:45 But in theory we do see contrast sites 19:49 and at least in animal models become healthier. 19:52 And that and then they can replicate and make new caller cells. 19:56 Right. 19:57 So I do think that may be our our bastion of some hope here. 20:02 We also know that GLP ones, interestingly enough, besides their 20:05 anti-inflammatory effect, may have some boost 20:09 on some of the condo sites in terms of helping them to be healthier as well. 20:13 So dependent of weight loss, independent of metabolic changes, 20:18 that we are seeing some improvement in cartilage 20:20 in animal studies with the GLP ones, even at low doses. 20:24 So I do think that there's a role of peptides that are outside 20:27 those traditional ones 20:28 that we're used to looking at, you know, the peaks and valleys of the 500. 20:32 And we probably need to be looking more into the mitochondrial realm, 20:35 which is kind of my belief of anything. 20:37 Well, it comes down to and it's so interesting 20:42 how everything comes back to the mitochondria, I know. 20:45 Right. 20:45 While yes, I just got involved with a not for profit 20:49 called countdown and their sole, I'm talking to them to now. 20:53 You okay? 20:54 Their mission is to fund mitochondrial research. 20:57 Like one of the podcasts that I did this year, I released, 21:01 I think it was this year or late last year that blew my like. 21:04 I literally had to go lie down after recording. 21:06 It was with the biotech company who are basically 21:10 have mastered transplanting healthy mitochondria into cells that are lacking 21:15 mitochondria and then reintroducing those back into bone marrow. 21:20 Right. 21:20 And seeing like the propagation and all of a sudden you see a whole body start to 21:27 better, right? 21:28 And to regenerate. 21:29 Like I see that with mitochondrial transplants that we can't 21:32 truly regrow tissue with mitochondrial transplants. 21:36 And so we it does really come down to those are the energy sources 21:39 within the cell. 21:40 And there are where our focus needs to be. 21:43 Yeah I love what Countdown's doing, because I think that this is 21:46 where our focus has to be for every single disease, 21:49 including some of these diseases. 21:50 We don't really think of mitochondrial diseases, which arthritis 21:53 may well be more so than we noticed too. 21:56 Yeah. Yeah. 21:57 No. And I it's and you know and the mitochondrial peptides are again 22:01 they're very interesting. 22:02 And we can go back a little bit to last week. 22:05 You know, what's interesting is because of the way the FDA functions, 22:09 they're not in a world where they're going to say, 22:12 oh, we're going to assess moxie for mitochondrial health. 22:16 They decided that where they got this from that mozzie would be measured 22:20 against its efficacy to treat osteoporosis, 22:23 which based on this conversation, is not maybe out of the question, but 22:28 it certainly is not where our, you know, where we look at using SC so much, right? 22:33 No, it is very interesting. 22:35 One of the problems 22:35 with the FDA shows and again, we weren't trying to prove efficacy in this hearing. 22:40 But the as they as they go down the road, you have to take basically 22:44 for an FDA approval of a drug, it has to be for a certain indication. 22:47 So BPC was going in for ulcerative colitis, right. 22:51 You might ask for us to process 22:54 epithelial on for insomnia for Sonia. Right. 22:57 That's not where we use these drugs or these peptides. 23:00 And so it is a little bit again to try and you know, to try. 23:04 And once they get FDA approved for education then we could use them off label 23:08 for those indications. But right now they're not anywhere near that. 23:11 And I think it's going to be hard to get those indications approved 23:14 because we as we know that that's not the primary thing we're using it for. 23:18 Yeah, yeah. 23:19 It'll be you're right I think that could osteoporosis. 23:22 Could we I'm not that much into mitochondrial or using a mystical process. 23:26 Patients using mitochondrial peptides that much enough. 23:29 But maybe it's something to look at. 23:30 Maybe there is more of a piece there. 23:32 As we talk about the, 23:33 you know, the role of mitochondria and everything, including muscle loss. 23:36 Right? It's just the only problem. 23:38 I think the challenge with that is if we think about how the body works 23:42 when we introduce any compound into the system, 23:45 certainly when it comes to peptides or, you know, if you 23:48 if you've listened to any of its podcasts from Young Goose, 23:53 the body is going to prioritize the tissue or the or the application 23:58 that it considers is the most is the greatest threat to your survival. 24:02 So you bring Mozzie into your body. 24:06 Is it going to consider the bones first, or is it going to consider your brain 24:10 that might be lacking 24:11 mitochondrial energy, or is it going to consider something else 24:14 like we you know, it'll be very interesting to see 24:18 how anybody thinks, like if we're going to to measure Moses 24:22 efficacy against osteoporosis, are we injecting it into bones? 24:27 Are we like like how would we do that? 24:30 The other thing would you remember about what I see is it actually only acts 24:33 as a sickly molecule when exercise is put in. 24:37 Right. 24:37 So that's the only problem is people are injecting modesty 24:40 thinking it's going to be sort of an exercise 24:42 because that's how it's been advertised is an exercise enhancer 24:45 without exercise, quite frankly, it doesn't have the similar needs. 24:50 And that's really where when you look at it for osteoporosis, 24:52 maybe because if I could stimulate muscle, muscle 24:56 actually makes my Myakka that actually help both. 24:59 We know that muscle is conducive to bone growth, right? 25:03 But what I see given in somebody who is laying in bed will do absolutely nothing. 25:08 It's an interesting peptide in that it's only signal occurs 25:11 when it's given on top of exercise. 25:15 So, you know, if I have somebody who's completely unable to exercise, 25:19 Maya C is not going to be something I can go to. 25:22 I need to go to something 25:24 that helps the mitochondria to function better, like human in like guesses. 25:27 31 elaborated. 25:29 Those would be my first choices to get the mitochondria healthy enough. 25:32 Now I can get the person maybe moving and add modesty on board, right? 25:36 And then, yes, if I have modesty on board and I'm exercising and helping 25:41 muscle growth, can I then say muscle growth is going to help? 25:44 But one, most certainly I can't. 25:45 But it's sort of a, you know, a distant down the road. 25:48 Yeah, it's a multi-step process. Okay. 25:51 So before we close up, one other way that we see people really using the BPC 25:57 with the TB 500 combo, and sometimes they'll stack on growth hormone,
Mitochondria, Cartilage, and Regeneration 26:02 which we don't need to talk about right at this minute. 26:03 But and they will do. 26:05 They're like, well, I just use them all the time for anti-aging purposes. 26:09 I'd love for you to address this because it makes my skin crawl a little bit. 26:14 I just, I and, you know, I'm starting to feel 26:17 like a really old woman at this point because I feel like I'm the one. 26:20 I'm like, I feel like I'm always pumping the brakes. 26:23 But it just seems to me that 26:26 because the way that peptides have come up and they've kind of captured 26:31 the imagination and the enthusiasm of these of people 26:37 who just want to do things on their own kind of thing. 26:41 There's all kinds of stuff flying around right now 26:44 which, which is it's concerning. Right. 26:47 And in a world where we're trying to get the FDA to move on their opinion 26:52 on this stuff, the last thing we need is somebody actually doing something 26:56 and hurting themselves, because that's all they need to say. 27:00 You see, I told you so. 27:02 Can we just and there's a million of these we could address. 27:05 But because we're talking about BPC and TB 500. 27:08 I'd love for you to talk about clinically how you're helping your patients 27:12 to figure out how often do I use it. 27:15 Do I using it the heavy training cycles? 27:18 How long is it safe to use? 27:21 Maybe if we're not seeing any results, it says that mean you haven't actually 27:24 gotten to the bottom of it. 27:25 Maybe you need to take care of your mitochondria, like, right. 27:28 That kind of stuff. 27:29 So first of all, I think that BPC and TD 500 need to be separated out 27:33 because from a safety profile, probably you would do no harm by running 27:37 BPC continuously okay versus TD 500, 27:41 which potentially we are going to create more vascular 27:45 growth to things and are we going to cause and there's no real data support. 27:49 But could you potentially enhance tumor growth. 27:52 Certainly from a mechanistic perspective that that's the case. 27:55 But a caveat that was saying I don't think anything we do 28:00 short of some very basics, 28:01 like your B vitamins and your magnesium and your feet should be run continuously. 28:06 It's not a way our body works. 28:08 A body doesn't like to be signaled continuously all the time. 28:13 In one way, 28:14 you'll actually change the body's entire responses by giving a continuous, 28:19 ongoing stimulus as opposed to a pulse of tile stimulus used appropriately, 28:24 timed appropriately, and with other things you're doing right. So. 28:29 So I like to use EPC 500 and kind of my more growth phases. 28:34 Right. 28:34 So in like a spring. 28:36 And some of you guys heard me talk about using peptides 28:38 sort of seasonally, is that there's times when our body is meant to sort of 28:41 just settle down or we shouldn't be pushing that. 28:45 Winter is really that time. 28:47 What are we decided to do in winter? 28:48 We're designed to actually sort of hibernate. 28:50 That's what most animals do. 28:52 So very interestingly, a lot of our receptors to things 28:56 like our growth hormone receptors become much less responsive 29:01 during those seasons, 29:02 even though we sort of say our circadian clocks are all messed up 29:05 because we don't we live in this controlled environments. 29:07 It's not the case. 29:08 Our bodies still have a Cirque annual rhythm, 29:12 because they're getting a rhythm means that if I pound growth hormone 29:17 and it's winter, my receptors are much less likely to respond, 29:22 and I am more likely 29:23 to actually see some downsides effects from that or some effects. 29:27 I don't want more edema, more things that I don't really want to see with these. 29:31 So I like to use peptides kind of cyclically with the seasons. 29:35 So my I always think about like sort of springtime as our growth rebirth. 29:39 That's our time of growing. 29:41 Use your growth go a little harder 29:42 because that's what you're going to hit your BBQs, your thigh. 29:45 And then again, potentially in the in the fall 29:48 as we're getting into the winter 29:49 time, you know, and then summer again a little bit more of a laid back time. 29:53 So unless I'm treating injuries in the summer 29:55 I lay back off those things a little. 29:57 I'm more relaxed adult you know, so and then using my by myself for one 30:02 my more immune modulating peptides are going to be doing, 30:04 you know, as I'm getting into that, you know, 30:06 sort of 30:06 spring the auto when everybody's getting sick and people are, 30:09 you know, deciding when they want to get back seasons and things. 30:11 So I like to always use things in cyclical matters. 30:14 And it's really the way our body has designed itself to work. 30:18 And there's a lot of evidence on this. 30:20 When you look at responsiveness of people in labs and other studies, 30:24 when they cycle things, 30:26 they get much more robust responses than running them continuously. 30:30 And again, I will tell you that very few things that I run 30:34 continuously, a handful of my supplements, I run continuous. 30:37 Otherwise I cycle things through. 30:40 It's really just, 30:41 you know, if you think mechanistically, 30:42 our body was never designed to be pounded with something all the time. 30:45 Yeah, like reminded all the time. Hello, hello. 30:48 Right, right, right. 30:49 And so uses a signaling molecules appropriately 30:52 to the time that you that you want certain results. 30:55 Right. 30:55 So if I'm going to be, you know, 30:57 my autumn gained a winner, I want to maybe push a little bit harder. 31:00 Food is robust. 31:01 Think about exactly what you know what happens in animal world, right? 31:04 Food is more robust. In the autumn. 31:05 We have all this food coming out of a harvest is coming in. I'm in. 31:08 Eat a little bit more. I'm going to grow a little bit more on a bulk. 31:10 I'm going to use my growth. 31:11 So guys, I'll maybe go higher on my anabolic hormones. 31:14 I'll maybe hit with my BPC, my growth, my, you know, regenerative peptides. 31:18 And then once I can lay off. 31:19 Right. 31:20 Yeah. 31:20 Relax a little bit, you know, and it just makes number one. 31:23 It helps with cost. 31:24 Number two it helps with fatigue of having to do these injections all the time. 31:29 And there were three. 31:30 You're going to get better responsiveness with less adverse events. 31:33 Thank you. 31:34 That was great. 31:34 So you mentioned TB five. 31:36 Now when you talk about TB 500 you're talking about TB 500 31:39 not TB for or like what is the FDA looking at here. 31:42 Are they looking at the 43 amino acid peptide or are they looking at 31:46 what's TB 500. 31:47 So when you so recently we went after TB 574 31:51 because I honestly quite frankly I use TD for much more often 31:54 than I used to 500 we went after TB 500 because it's a smaller peptide. 31:59 It's a frightened right. 32:00 And so as you got into the 43 amino acid, you start pushing into that 32:06 biologic role that the FDA is not going to be happy with. 32:10 Right. 32:10 So we went after the TV 500 because it's a much safer zone where that fragment 32:15 was much easier to pass through in these regulations, you know. 32:20 So TD TB for unfortunately is going to stay in this kind of maybe 32:24 pushing into the biologic zone where it's going to be hard to be able 32:27 to get compounding pharmacies to be able to really such a shame 32:31 because it's such a powerful from a value of, 32:34 you know, I'm using them a little bit interchangeably and that, 32:36 you know, I'm more of a fan of TB four than I am a TD 500. 32:41 Same. 32:41 Well, because it has all these immune options as well. 32:44 Immune effects. Right. 32:45 It is the peptide our thymus gland makes right. 32:47 You know so for 1000 for those are the peptides our thymus land makes 32:53 before we don't have a diverse anymore which is you know by the time 25. 32:57 Yeah. Right. So not a bad thing to bring on board. 32:59 Although anyway some very cool stuff going on in that thymus regeneration role
Cycling Peptides and Practical Use 33:03 beyond just like the, you know, the studies that were going on 33:06 with just using, you know, growth hormones and all those things that were going on. 33:09 There's actually some really cool research going on with actually regenerating 33:13 the thymus gland. 33:14 So as you talked about with this, you know, being able to regenerate. 33:17 There are some very interesting companies I heard present recently 33:21 that are doing some very remarkable things with dinosaur regeneration, 33:25 which will be a game changer because our thymus degradation, you know, 33:28 as we age, is one of the things that's responsible 33:30 for us getting cancer and getting, you know, viruses. 33:33 And we're doing the best we can with assignment cut ties. 33:36 Those are certainly useful. 33:37 But if we could actually have a new thymus, that would be great. 33:39 And what are they using? 33:41 So the whole technology was a little bit odd. 33:44 Me so kind of light or substances like energy 33:48 or substance to know it was actually regenerate. 33:50 So they were actually able to regenerate a thymus gland. 33:53 And wow, the technology was a little beyond me. 33:56 But all right. 33:57 But we'll record a podcast on that or we'll get or get the researcher 34:00 doing it to get the researcher to come into my guest with us. 34:03 Okay. Thank you. That was phenomenal. 34:06 I mean, you know, 34:07 we could go a lot deeper, but hopefully people walk away from this with better 34:12 understanding of what's happening with peptides from a regulatory perspective, 34:15 some better understanding of the BPC and thymus and TB 500 34:19 in terms of what they can do. 34:20 And sometimes they don't work right. 34:22 How the mitochondrial peptides may or may not help out in these situations. 34:27 The last thing I wanted to ask you 34:28 actually, before we go is you've mentioned blood vessel 34:32 like blood flow regeneration, like bringing more blood to the area. 34:36 But you mentioned it in context of TB 500, not BPC 157. 34:40 Isn't BPC 157 also known for stimulating angiogenesis? 34:44 But yeah, but it is much more homeostatic. 34:48 So we will never create this huge robust vascularization. 34:53 It's very homeostatic. So it's never been shown. 34:56 Any studies have shown that you would over vascularized 34:59 to create feeding blood vessels to tissue that you don't want. 35:02 Okay. 35:03 So the studies on and again it's not a lot of compelling data 35:06 even with the TB for CB 500 down that shows that either. 35:09 But if we were to look mechanistically Deep-Sea is so homeostatic we use the BPC 35:15 somehow knows it is very much knows when to stop and when to grow. 35:19 And so it's a much more interesting cup tie from that role. 35:22 Yeah. 35:22 Well and I think because it's so pleiotropic will be the one that evades 35:26 categorization the longest. Right. 35:28 Because it does so many different things anyway. Things right. 35:31 So many things we can. 35:33 Yeah. 35:33 But but we digress. 35:34 So folks, hopefully you got some 35:38 incredibly valuable tidbits out of this short conversation. 35:41 Doctor, you're thank you so much for taking the time 35:43 out of your insane schedule to do this. 35:47 Why don't we let people know where to 35:49 find you and follow the work that you're doing? 35:52 So, guys, you can always join our academy Bleed Academy. 35:56 We do these great monthly Q&A and they're really fun. 35:59 People ask really, really good questions 36:00 and it's, you know, open to physicians and lay people, whoever wants to join. 36:04 But people who are just want to learn more about functional medicine, peptides. 36:08 And then we just go through a list of questions that people send. 36:11 And it's very fun. 36:12 Some academy, you can come to our website, forlongevity.com 36:17 we see patients from all over the country. 36:19 So we are I'm licensed in 48 of 50 states so we can see patients all over. 36:24 And certainly one of my passions arthritis. 36:26 So we do a lot of work in that realm as well. 36:28 So usually that involves him to fly out here for things. 36:31 But we can do a lot online to with our patients or helping people surgery to. 36:35 I think that's a big place where we need to be 36:36 easy peptides more using that pre and post surgical population, 36:39 because I think they sort of have sort of resigned 36:42 to the typical orthopedic doctor who doesn't know anything about these, 36:44 and they need to be working together with us. 36:46 Yeah for sure. Thank you so much. 36:49 This has been a pleasure as always. 36:51 Thank you always.
Comments